



NDA 22-026

NDA APPROVAL

Synthon Pharmaceuticals, Inc.
Attention: Mr. Michael Hinckle
9000 Development Drive
P.O. Box 110487
Research Triangle Park, North Carolina 27709

Dear Mr. Hinckle:

Please refer to your January 31, 2006 new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Amlodipine 2.5, 5 and 10 mg Orally Disintegrating Tablets.

We acknowledge receipt of your submissions dated March 27 and June 13, 2007.

The March 27, 2007 submission constituted a complete response to our December 1, 2006 action letter.

This new drug application provides for the use of Amlodipine Orally Disintegrating Tablets (2.5, 5, and 10 mg) for the treatment of hypertension.

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

The proposed dissolution method and specifications are as follows: USP Type II apparatus at a paddle speed of 50 rpm in 500 mL of 0.01 M HCl with a Q in 15 minutes.

An expiration date of 24 months is granted for Amlodipine Orally Disintegrating Tablets.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 22-026." You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Container Labels for approved NDA 22-026.**” Approval of this submission by FDA is not required before the labeling is used. We note that you will not use cartons for this product.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROPRIETARY NAME

If you choose to use a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit any proprietary name to the Agency for our review prior to its implementation.

PEDIATRIC RESEARCH EQUITY ACT (PREA)

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

METHODS VALIDATION

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Denise Hinton, Regulatory Project Manager, at (301) 796-1090.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal
Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure (Agreed-upon labeling text)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
9/27/2007 04:59:22 PM